At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,030 enrolled
Drug / intervention
Nitazoxanide +1 moredrug
Likely dose
Nitazoxanide 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza
In Brief
A Phase 3 clinical trial evaluating Nitazoxanide and Placebo for Influenza. Completed, enrolled 1,030 participants across 38 sites in 3 countries.
Detailed Summary
Trial to evaluate efficacy and safety of nitazoxanide (NTZ) in the treatment of uncomplicated influenza.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesAustralia, Puerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartJan 2018
Primary CompletionApr 2019
TodayJul 2026
First PostedNov 8, 2017
Enrollment StartJan 17, 2018
Primary CompletionApr 17, 2019
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 8.7 years ago
Interventions
Nitazoxanidedrug
Nitazoxanide 600 mg administered orally twice daily for five days
Placebodrug
Placebo administered orally twice daily for five days